> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Regulatory Review Period Corrected for Enspryng
- URL: https://www.fdaweb.com/regulatory-review-period-corrected-for-enspryng/
- Published: 2023-05-23T12:00:00.000Z
- Updated: 2026-09-14T18:33:48.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5154513

*Federal Register* notice: FDA is correcting a 7/13/2022 notice that announced the regulatory review period determination for Genentech’s Enspryng (satralizumab-mwge), indicated for treating neuromyelitis optica spectrum disorder in adult patients who are anti-aquaporin-4 antibody positive. The original notice should have stated that the regulatory review period is 2,494 days, of which 2,128 days occurred during the testing phase and 366 days during the approval phase.” To view the notice, click [here](https://public-inspection.federalregister.gov/2023-10979.pdf?ref=fdaweb.com).